title: Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.
abstract: There is relatively little information in the literature on the histopathology of chronic hepatitis C in children. The Peds-C Trial, designed to test the efficacy and safety of peginterferon alfa-2a and ribavirin in children, provided an opportunity to examine liver biopsies from 121 treatment-naïve children, ages 2 to 16 (mean, 9.8 years) infected with the hepatitis C virus (HCV) and with no other identifiable cause for liver disease, signs of hepatic decompensation, or another significant nonhepatic disease. Liver biopsies were scored for inflammation, fibrosis, steatosis, and other histological features. Inflammation in the biopsy was minimal in 42%, mild in 17%, moderate in 38%, and severe in only 3%. Five had bridging fibrosis, and 2 had cirrhosis. Steatosis was absent in 56%, minimal in 34%, and mild in 10%. Inflammation scores correlated with fibrosis scores, serum alanine aminotransferase levels, and duration of infection, but not with age, body mass index z score, or HCV genotype. Fibrosis scores correlated with inflammation but not with age, HCV genotype, body mass index z score, or steatosis parameters. Steatosis correlated with serum alanine aminotransferase levels and body mass index z scores; overweight children had more fibrosis than the non-overweight. In conclusion, in this cohort of HCV-infected children, inflammation, fibrosis, and steatosis were milder than reported for treatment-naïve adults with chronic hepatitis C, but there were several with bridging fibrosis or cirrhosis. The positive correlation of inflammation with duration of infection and fibrosis and of obesity with fibrosis suggest that children with chronic hepatitis C will be at risk for progressive liver disease as they age and possibly acquire other comorbid risk factors.
authors.affiliation: Armed Forces Institute of Pathology and Veterans Administration Special Reference Laboratory for Pathology, Washington, DC, USA. Goodman@afip.osd.mil
authors.forename: Zachary D
authors.initials: ZD
authors.lastname: Goodman
authors.forename: Hala R
authors.initials: HR
authors.lastname: Makhlouf
authors.forename: Lea
authors.initials: L
authors.lastname: Liu
authors.forename: William
authors.initials: W
authors.lastname: Balistreri
authors.forename: Regino P
authors.initials: RP
authors.lastname: Gonzalez-Peralta
authors.forename: Barbara
authors.initials: B
authors.lastname: Haber
authors.forename: Maureen M
authors.initials: MM
authors.lastname: Jonas
authors.forename: Parvathi
authors.initials: P
authors.lastname: Mohan
authors.forename: Jean P
authors.initials: JP
authors.lastname: Molleston
authors.forename: Karen F
authors.initials: KF
authors.lastname: Murray
authors.forename: Michael R
authors.initials: MR
authors.lastname: Narkewicz
authors.forename: Philip
authors.initials: P
authors.lastname: Rosenthal
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Smith
authors.forename: Patricia R
authors.initials: PR
authors.lastname: Robuck
authors.forename: Kathleen B
authors.initials: KB
authors.lastname: Schwarz
mesh_terms: D000293:Adolescent; D000328:Adult; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a